Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2021-03-16 Earnings Release
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Innate Pharma announces conference call and webcast for Full Year 2020 financial results
Earnings Release Classification · 98% confidence The document is titled "INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FULL YEAR 2020 FINANCIAL RESULTS". It explicitly states the purpose is to announce a conference call following the release of financial results for the year ending December 31, 2020. This announcement provides details on how to join the call (webcast link, dial-in numbers) and who will be presenting. This structure—announcing a call to discuss results—is characteristic of an Earnings Release (ER) or, more specifically, the announcement leading up to the discussion of those results, which often overlaps with the content of an Earnings Release or a Call Transcript announcement. Since the document is an announcement *about* the call where results will be discussed, and it is not the transcript itself, nor the full 10-K, the most fitting category is Earnings Release (ER), as it pertains directly to the communication of period-end financial performance highlights. It is not a Call Transcript (CT) because it is the announcement, not the transcript of the discussion. FY 2020
2021-03-16 English
Innate Pharma organise une conférence téléphonique et un webcast pour ses résultats financiers 2020
Report Publication Announcement Classification · 90% confidence The document is a press release announcing a conference call and webcast scheduled for March 18, 2021, following the publication of the company's financial results for the fiscal year ended December 31, 2020. This document itself is not the full financial report (10-K or IR), nor is it the initial earnings highlights (ER). Instead, it is an announcement providing details (date, time, access links) for a discussion about those results, which typically involves management commentary and Q&A. This strongly aligns with the definition of a Call Transcript (CT) if the text provided was the transcript itself, but since this document is *announcing* the call where the results will be discussed, it functions as a precursor or related announcement. However, the key focus is the upcoming discussion of financial results. If the document were the actual transcript, it would be 'CT'. If it were the initial results summary, it would be 'ER'. Since it is an announcement *about* the call where results will be discussed, and given the options, it is most closely related to the event where earnings are discussed. In many contexts, an announcement for an earnings call is often classified alongside the Earnings Release (ER) or sometimes as a general Regulatory Filing (RNS) if no better fit exists. Given the explicit mention of 'RÉSULTATS FINANCIERS 2020' and the scheduling of a call to discuss them, the most relevant category describing the *event* being promoted is the Earnings Release (ER) context, or potentially a Call Transcript (CT) if the content was the transcript. Since this is the *invitation* to the call, and it is not a generic regulatory filing, the closest fit among the specific financial reporting types is ER, as it pertains directly to the release of period results, even if it's the announcement of the follow-up call. However, if we strictly follow the definitions, this is an announcement about a future event where results will be discussed. If the document were the actual transcript, it would be CT. If it were the initial results summary, it would be ER. Since it is an announcement *of* the call, it is often categorized as a Report Publication Announcement (RPA) if it were announcing the release of a document, or RNS if it's a general announcement. Given the context is explicitly about the *financial results* discussion, and it's not the results themselves, I will classify it as a Report Publication Announcement (RPA) because it announces the details of the event where the results will be presented/discussed, which is a common pattern for pre-earnings call announcements, or RNS as a fallback. Re-evaluating: The document is a press release detailing the logistics for the conference call discussing the 2020 financial results. This is a common precursor to an Earnings Release (ER) or Call Transcript (CT). Since it is not the actual results summary (ER) or the transcript (CT), and it is a formal announcement, RPA (Report Publication Announcement) fits best as it announces the publication/discussion event, or RNS as a general regulatory announcement. Given the strong link to financial results, I lean towards RPA as it announces the event where the results will be discussed, similar to announcing a report publication.
2021-03-16 French
FORM 6-K
Foreign Filer Report
2021-02-24 English
Number of shares and voting rights of Innate Pharma as of February 1, 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states its purpose: to release the 'Total number of shares outstanding as well as its voting rights as of February 1, 2021,' citing compliance with French Commercial Code and AMF regulations (Article L. 233-8 II and Article 223-16). This type of mandatory disclosure regarding the total share count and voting rights is a specific regulatory filing, often related to major shareholding notifications or general corporate structure updates, but it is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Since it details the number of shares and voting rights, it most closely aligns with a notification concerning share capital structure or major holdings. Given the options, 'Major Shareholding Notification' (MRQ) is the closest fit for a mandatory disclosure detailing the total number of shares and voting rights, as these figures are the basis for calculating shareholding thresholds. However, since the document is a direct regulatory disclosure of share count mandated by the AMF, and not explicitly a notification *of a change* in a major shareholder crossing a threshold, the most appropriate general category for mandatory, non-financial, structure-related regulatory announcements that don't fit elsewhere is 'Regulatory Filings' (RNS). Upon re-evaluation against the definitions, the content is a direct regulatory disclosure of share capital structure information required by the regulator, which is a common component of filings related to share ownership thresholds. If a specific 'Share Capital/Voting Rights Disclosure' code existed, it would be used. Lacking that, MRQ (Major Shareholding Notification) is often used for these disclosures, but RNS (Regulatory Filings) is the safest fallback for specific, non-standard regulatory announcements. Given the precise nature of the data (total shares/voting rights), and its relation to shareholding thresholds, MRQ is a strong candidate, but RNS covers general regulatory announcements best. I will select RNS as it is a direct regulatory filing mandated by the AMF that doesn't fit the other specific financial/meeting/management categories.
2021-02-24 English
Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er février 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER FEVRIER 2021" (New number of shares and voting rights as of February 1, 2021) and explicitly states it is published in accordance with French Commercial Code articles and AMF regulations (Autorité des marchés financiers). It details the total number of ordinary shares, preference shares, theoretical voting rights, and exercisable voting rights as of a specific date. This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement, often related to capital structure changes or mandatory periodic updates. While it relates to the share count, it is not a general share issue announcement (SHA) or a transaction in own shares (POS), but rather a mandatory disclosure of the current state of the capital base and voting power. This fits best under the general category for regulatory announcements that don't fit elsewhere, or potentially a specific capital structure update. Given the focus on the total count of shares and voting rights as required by the AMF, it is a specific regulatory disclosure. Since there isn't a perfect fit for 'Share Capital/Voting Rights Disclosure', and it is a formal regulatory announcement concerning the capital structure, it aligns closely with the nature of mandatory regulatory filings. However, the content is specifically about the number of shares and voting rights, which is a key component of capital structure reporting. Comparing the options, 'SHA' (Share Issue/Capital Change) is close, but this is a periodic report of the *current* state, not an announcement of a *change* being executed. 'MRQ' (Major Shareholding Notification) is for changes crossing thresholds. The most appropriate category for a mandatory, periodic disclosure of the total share capital and voting rights, especially when referencing specific regulatory articles (L. 233-8 II du Code de Commerce and 223-16 du règlement général de l'AMF), is often captured under general regulatory filings if a more specific code isn't available. Given the options, and recognizing this is a formal disclosure about the capital base, it is most analogous to a capital structure update, but since it's a mandatory disclosure of the *current* count, 'RNS' (Regulatory Filings) serves as the best general fit for mandatory, non-periodic financial/structural updates that aren't earnings or management changes. If 'SHA' implies any report about shares, it could fit, but 'SHA' usually implies an action (issue/split). I will classify this as a specific regulatory filing (RNS) as it is a mandatory disclosure of capital structure metrics required by the regulator, which is a common use case for RNS.
2021-02-24 French
FORM 6-K
Foreign Filer Report
2021-02-17 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.